Editas Medicine (EDIT) Short term Debt (2024 - 2025)
Editas Medicine (EDIT) posted quarterly Short term Debt of $5.0 million for Q4 2025, little changed year-over-year from $5.0 million in Q4 2024, and little changed quarter-over-quarter from $5.0 million in Q3 2025.
Powered by 
Analysis
Editas Medicine (EDIT) Short term Debt (2024 - 2025) Analysis & Trends
Editas Medicine (EDIT) has reported Short term Debt for 2 consecutive years, with $5.0 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Short term Debt changed 0.0% year-over-year to $5.0 million; the TTM figure through Dec 2025 stood at $5.0 million (changed 0.0% YoY), while the FY2025 annual figure was $5.0 million, changed 0.0% from the prior year.
- Short term Debt was little changed at $5.0 million in Q4 2025 per EDIT's latest filing, from $5.0 million in the prior quarter.
- Across five years, Short term Debt topped out at $5.0 million in Q4 2024 and bottomed at $5.0 million in Q4 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn |
| 10 | Editas Medicine | 287.84 Mn | 141.19 Mn | - |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Dec 31, 2025 | 5.00 Mn |
| Sep 30, 2025 | 5.00 Mn |
| Jun 30, 2025 | 5.00 Mn |
| Mar 31, 2025 | 5.00 Mn |
| Dec 31, 2024 | 5.00 Mn |